SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950142-21-002677
Filing Date
2021-08-19
Accepted
2021-08-19 10:15:12
Documents
13
Period of Report
2021-08-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh210178862_8k.htm   iXBRL 8-K 28063
  Complete submission text file 0000950142-21-002677.txt   251441

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nrxp-20210818.xsd EX-101.SCH 3767
3 XBRL DEFINITION FILE nrxp-20210818_def.xml EX-101.DEF 27735
4 XBRL LABEL FILE nrxp-20210818_lab.xml EX-101.LAB 36811
5 XBRL PRESENTATION FILE nrxp-20210818_pre.xml EX-101.PRE 26353
6 EXTRACTED XBRL INSTANCE DOCUMENT eh210178862_8k_htm.xml XML 5574
Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 211188732
SIC: 2834 Pharmaceutical Preparations